AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'

The article highlights bullish analyst and investor calls across Coca-Cola, AbbVie, Sabra Health Care REIT, and UnitedHealth, with price targets raised on Coca-Cola to $89 and UnitedHealth to $450. AbbVie also received European Commission authorization to expand the label for VENCLYXTO in previously untreated chronic lymphocytic leukemia, while Sabra reported better-than-expected Q1 results. The stocks referenced traded higher on the session, with UnitedHealth up 0.8%, AbbVie up 1.0%, Coca-Cola up 3.5%, and Sabra Health Care up 4.5%.

Analysis

The common thread here is not “four stock picks,” but a late-cycle quality bid into businesses with visible earnings durability and lower event risk. That tends to compress dispersion in the near term: capital rotates toward names with incremental analyst support, regulatory optionality, or evidence of execution, while weaker balance-sheet stories get starved of attention. In that regime, the best relative-value expression is often not outright longs, but long/short spreads against slower-growth defensives or valuation-rich healthcare leaders where expectations have already reset.

ABBV and UNH have the cleanest second-order catalysts because both are being re-rated by external validation rather than internal hype. For ABBV, the European label expansion broadens the addressable share of a franchise that already behaves like an annuity; the key implication is less peak sales than longer duration of cash flows, which can support buybacks and keep leverage on a declining path. For UNH, the upgrade matters more than the price target: once the market believes the earnings revision cycle has turned, downside volatility usually collapses and the stock can outperform even without multiple expansion.

SBRA is the most interesting contrarian setup because it sits at the intersection of rate sensitivity and operating recovery. If rates stabilize, healthcare REITs can see a fast re-rating from “capital structure risk” to “cash flow yield,” but the upside is highly dependent on continued occupancy and tenant credit discipline over the next 2–3 quarters. KO is the least compelling on a standalone basis: the bullish case is defensive capital rotation, but at this point the better trade is probably as a funding source for higher-beta quality names rather than a fresh long.

Key Decisions for Investors

• Long ABBV vs short a basket of large-cap healthcare laggards over the next 4–8 weeks; target 5–8% relative outperformance if the label-expansion narrative attracts incremental revision buying, with stop if the pair underperforms by 3% on no follow-through.
• Initiate a tactical long UNH on weakness for a 1–3 month window; this is a lower-volatility expression of earnings revision momentum with a favorable risk/reward as long as the stock holds above the post-upgrade support zone.
• Consider SBRA only as a smaller-sized yield/recovery trade over 2–3 quarters; pair it against a higher-leverage healthcare REIT or rate-sensitive REIT basket to isolate operating improvement from duration risk.
• Use KO as a source of funds rather than a new beta allocation unless the market enters a defensive panic phase; upside here is likely capped versus the healthcare names, so the opportunity cost is high.
• If real yields move higher, rotate out of SBRA first and keep ABBV/UNH only as core quality longs; that sequencing should preserve capital while maintaining exposure to the stronger earnings-revision names.